118 related articles for article (PubMed ID: 15750451)
1. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.
Corey SJ; Elopre M; Weitman S; Rytting ME; Robinson LJ; Rumelhart S; Goldman FD
J Pediatr Hematol Oncol; 2005 Mar; 27(3):166-8. PubMed ID: 15750451
[TBL] [Abstract][Full Text] [Related]
2. Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone marrow transplantation or cell therapy (SFGM-TC).
Grain A; Sirvent A; Strullu M; Françoise M; Mohty M; Guillaume T; Chevallier P; Rialland F
Leuk Lymphoma; 2016 Dec; 57(12):2937-2941. PubMed ID: 27184944
[No Abstract] [Full Text] [Related]
3. Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia.
Douer D; Watkins K; Levine AM; Weiss JM; Marshall LC; Craig AR
Leuk Lymphoma; 2003 Dec; 44(12):2135-6. PubMed ID: 14959859
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia.
Aoki Y; Miyawaki R; Imai K; Takagi M; Kajiwara M; Ishiwata Y; Yasuhara M; Morio T; Mizutani S; Tomizawa D
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e39-41. PubMed ID: 26523380
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
6. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.
Burnett AK; Russell NH; Hunter AE; Milligan D; Knapper S; Wheatley K; Yin J; McMullin MF; Ali S; Bowen D; Hills RK;
Blood; 2013 Aug; 122(8):1384-94. PubMed ID: 23838349
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Choi J; Foss F
Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.
Locke FL; Artz A; Rich E; Zhang Y; van Besien K; Stock W
Bone Marrow Transplant; 2010 Dec; 45(12):1692-8. PubMed ID: 20208570
[TBL] [Abstract][Full Text] [Related]
9. Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Loeffler C; Kapp M; Grigoleit GU; Mielke S; Loeffler J; Heuschmann PU; Malzahn U; Hupp E; Einsele H; Stuhler G
Leuk Lymphoma; 2015; 56(12):3365-9. PubMed ID: 26014275
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
Suo P; Zhang LP; Wu J; Lu AD; Wang B; Zuo YX; Cheng YF; Liu GL
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):444-7. PubMed ID: 23791059
[TBL] [Abstract][Full Text] [Related]
11. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
Leukemia; 2016 Feb; 30(2):261-7. PubMed ID: 26283567
[TBL] [Abstract][Full Text] [Related]
12. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of JMML relapsed after unrelated allogeneic transplant with cytoreduction followed by DLI and interferon-alpha: evidence for a graft-versus-leukemia effect in non-monosomy-7 JMML.
Pulsipher MA; Adams RH; Asch J; Petersen FB
Bone Marrow Transplant; 2004 Jan; 33(1):113-5. PubMed ID: 14704663
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
15. Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.
Ohta H; Kawai M; Sawada A; Tokimasa S; Fujisaki H; Matsuda Y; Osugi Y; Okada S; Hara J
Bone Marrow Transplant; 2000 Sep; 26(6):681-3. PubMed ID: 11041570
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.
Kantarjian HM; Erba HP; Claxton D; Arellano M; Lyons RM; Kovascovics T; Gabrilove J; Craig M; Douer D; Maris M; Petersdorf S; Shami PJ; Yeager AM; Eckert S; Abichandani R; Faderl S
J Clin Oncol; 2010 Feb; 28(4):549-55. PubMed ID: 20026805
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia.
Tischer J; Stemmler HJ; Engel N; Hubmann M; Fritsch S; Prevalsek D; Schulz C; Zoellner AK; Bücklein V; Hill W; Ledderose G; Hausmann A
Ann Hematol; 2013 Oct; 92(10):1379-88. PubMed ID: 23928857
[TBL] [Abstract][Full Text] [Related]
18. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy.
Racil Z; Toskova M; Dvorakova D; Jeziskova I; Razga F; Buresova L; Timilsina S; Mayer J
Am J Hematol; 2012 Feb; 87(2):211-3. PubMed ID: 22052688
[TBL] [Abstract][Full Text] [Related]
19. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.
Kebriaei P; Bassett R; Lyons G; Valdez B; Ledesma C; Rondon G; Oran B; Ciurea S; Alousi A; Popat U; Patel K; Ahmed S; Olson A; Bashir Q; Shah N; Jones R; Marin D; Rezvani K; Nieto Y; Khouri I; Qazilbash M; Hosing C; Shpall E; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2017 Feb; 23(2):285-292. PubMed ID: 27816651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
